EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Enabling evolutionary therapy in metastatic cancer lacking serum biomarkers

Eva Molnárová, Ties A Mulders, Marcela Spee-Dropková, Louise M Spekking, Sepinoud Azimi, Irene Grossmann, Anne-Marie C Dingemans, Kateřina Staňková

Journal of Evolutionary Biology · 10.09.2026

DOI: 10.1093/jeb/voag070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Evolutionary Biology, online erschienen am 10.09.2026. Verfasst von Eva Molnárová und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health Systems Science, Delft University of Technology, Faculty of Technology, Policy and Management, Delft, The Netherlands. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Dutch Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Evolutionary therapy (ET) aims to anticipate and steer tumour evolution by adjusting treatment timing and dosing, often to control rather than eradicate tumour burden. Clinical use requires reliable monitoring of tumour dynamics to inform mathematical models that guide therapy. In cancers such as metastatic castrate-resistant prostate cancer and relapsed platinum-sensitive ovarian cancer, ET models are informed by serial serum biomarkers. For cancers lacking reliable biomarkers, such as metastatic nonsmall cell lung cancer (NSCLC), radiographic imaging remains the primary method for treatment response assessment, typically using RECIST 1.1 criteria. RECIST, which tracks a limited number (up to five) of lesions with one-dimensional (1D) measurements and defines progression relative to the nadir, the smallest tumour burden recorded after treatment, was not designed to support ET. It may miss early regrowth, under-represent tumour burden, and obscure disease trends. Using a virtual NSCLC patient model, we demonstrate that lesion selection and measurement dimensionality strongly affect progression detection. Two-dimensional metrics provide modest improvement, but only 3D volumetric measurements accurately capture both tumour burden and its dynamics, which are key requirements for ET. To support ET in cancers lacking biomarkers, response assessment must evolve beyond RECIST by integrating volumetric imaging, automated segmentation, and potentially liquid biopsies, alongside redefining progression criteria to enable adaptive, patient-centred treatments.

Schlagwörter

Stichwörter der Autor:innen

humanssimulationtheory

Autor:innen und Institutionen

  • Institute for Health Systems Science, Delft University of Technology, Faculty of Technology, Policy and Management, Delft, The Netherlands.
  • Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Department of Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Department of Radiology, Groene Hart Ziekenhuis, Gouda, The Netherlands.

Förderung

  • Dutch Research Council

Zitieren

APA

Molnárová, E., Mulders, T. A., Spee-Dropková, M., Spekking, L. M., Azimi, S., Grossmann, I., Dingemans, A. C., & Staňková, K. (2026). Enabling evolutionary therapy in metastatic cancer lacking serum biomarkers. Journal of Evolutionary Biology. https://doi.org/10.1093/jeb/voag070

Vancouver

Molnárová E, Mulders TA, Spee-Dropková M, Spekking LM, Azimi S, Grossmann I, et al. Enabling evolutionary therapy in metastatic cancer lacking serum biomarkers. Journal of Evolutionary Biology. 2026. doi:10.1093/jeb/voag070

BibTeX
@article{Molnrov2026,
  author = {Molnárová, Eva and Mulders, Ties A and Spee-Dropková, Marcela and Spekking, Louise M and Azimi, Sepinoud and Grossmann, Irene and Dingemans, Anne-Marie C and Staňková, Kateřina},
  title = {Enabling evolutionary therapy in metastatic cancer lacking serum biomarkers},
  journal = {Journal of Evolutionary Biology},
  year = {2026},
  doi = {10.1093/jeb/voag070}
}
Kostenlos starten →